Advertisement

Topics

Latest "ObsEva Starts Phase Clinical Program Nolasiban" News Stories

15:16 EDT 18th September 2018 | BioPortfolio

Here are the most relevant search results for "ObsEva Starts Phase Clinical Program Nolasiban" found in our extensive news archives from over 250 global news sources.

More Information about ObsEva Starts Phase Clinical Program Nolasiban on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ObsEva Starts Phase Clinical Program Nolasiban for you to read. Along with our medical data and news we also list ObsEva Starts Phase Clinical Program Nolasiban Clinical Trials, which are updated daily. BioPortfolio also has a large database of ObsEva Starts Phase Clinical Program Nolasiban Companies for you to search.

Showing "ObsEva Starts Phase Clinical Program Nolasiban" News Articles 1–25 of 25,000+

Tuesday 18th September 2018

PetSmart® Provides Free Baths for Dogs in Flooded Areas

Pet Parents in Hurricane-Impacted Areas Can Bring Their Dogs to a Local PetSmart Grooming Salon for a Free Bath With thousands of residents still impacted by Hurricane Florence, PetSmart is offering free dog baths to help pet parents as they return to normalcy. Now through Saturday, September 22, from noon until close, PetSmart will off...


White House Delegation Visits Belden to Study Manufacturer’s Innovative Drug Abuse Prevention Program

Today, Belden Inc. introduced the company’s Pathways to Employment initiative to Second Lady Karen Pence, Secretary of Labor Alex Acosta, Surgeon General Dr. Jerome Adams and Counselor to the President Kellyanne Conway at its Richmond, Indiana plant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180...

Sickle Cell Anemia - A Drug Pipeline Analysis Report by Technavio

Technavio has announced their latest drug pipeline analysis report on sickle cell anemia. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of


Herpes Zoster - A Drug Pipeline Analysis Report by Technavio

Technavio has announced their latest drug pipeline analysis report on herpes zoster. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of

NIH Funds Hingez Therapeutics to Develop New Cholesterol Pill

Hingez’s Approach May Lead to Better Solutions for Treating High-Cholesterol, Other Diseases WASHINGTON (PRWEB) September 18, 2018 In August, Hingez Therapeutics Inc. received a grant totaling more than 1.8 million from the National Institutes of Health (NIH) to develop oral drugs to treat high cholesterol, with the goal of reaching human trials within two to three years. “Hingez Therapeutic...

STAT Plus: Facing criticism, CVS may modify its new cost-effectiveness program for setting coverage. https://buff.ly/2pjTw1Y pic.twitter.com/Y85k6SwVCN

STAT Plus: Facing criticism, CVS may modify its new cost-effectiveness program for setting coverage. https://buff.ly/2pjTw1Y  pic.twitter.com/Y85k6SwVCN

Children’s Hospital Los Angeles Team Identifies Developmental Stage for No. 1 Eye Tumor in Children

Finding in retinoblastoma could lead to new interventions Investigators at Children's Hospital Los Angeles have been able to pinpoint the exact stage of development of the human retina, when cells can grow out of control and form cancer-like masses. The finding could open the door for future interventions in retinoblastoma (RB), a tumor of the retina t...

Veritas Collaborative Rallies Eating Disorder Experts to Address Issues Facing Patients, Industry

Thought Leaders Kickstart Annual Symposium with Spotlight on Community, Collaboration DURHAM, N.C. (PRWEB) September 18, 2018 Veritas Collaborative, a specialty healthcare system for the treatment of eating disorders, kickstarted its seventh annual symposium on eating disorders by curating a collective of eating disorder experts from around the country to address the role community and collaborat...

HCW also 2nd drug VK5211 update soon; data, FDA, and potential partner, oh my. The VK5211 program is in a critical stage of its evolution following the strong randomized Phase 2 data in hip fracture patients announced in November 2017. $VKTX

HCW also 2nd drug VK5211 update soon; data, FDA, and potential partner, oh my. The VK5211 program is in a critical stage of its evolution following the strong randomized Phase 2 data in hip fracture patients announced in November 2017. $VKTX

Continuum Clinical Names Kevin Hartbarger as New VP, Media

Global patient recruitment and retention company, Continuum Clinical is proud to announce Kevin Hartbarger as its new vice president of media. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005943/en/

Life Spine Announces Record Sales Growth of SIMPACT® Sacroiliac Fixation System

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today continued accelerated market adoption and high sales growth for the SIMPACT Sacroiliac Joint Fixation system, since commercialization at the start of the 2018 calendar year. “Clinical econ...

$VKTX Effect on MRI-PDFF, which has become key Phase 2 surrogate endpoint for predicting #NASH biopsy improvement, is better than every other oral NASH drug-Even more impressive -76.9%&90.9% of patients QOD or QD dosing,were MRI-PDFF responders i.e., ≥3

$VKTX Effect on MRI-PDFF, which has become key Phase 2 surrogate endpoint for predicting #NASH biopsy improvement, is better than every other oral NASH drug-Even more impressive -76.9%&90.9% of patients QOD or QD dosing,were MRI-PDFF responders i.e., ≥30% reduction from baseline

RJ $VKTX looking for any meaningful weaknesses in the 45 patient dataset and quite frankly have not found any. The data beat even our optimistic expectations and we see the only advantage retained by $MDGL at this point being time-to-Phase 3.

RJ $VKTX looking for any meaningful weaknesses in the 45 patient dataset and quite frankly have not found any. The data beat even our optimistic expectations and we see the only advantage retained by $MDGL at this point being time-to-Phase 3.

LUMEDX Rolls Out Comprehensive Cardiovascular Information System at Major Academic Medical Center

Structured reporting, analytics and automated data acquisition cited as key to best-practice CV management LUMEDX Corporation, a provider of wholly integrated cardiovascular data intelligence and imaging solutions, announced today that it is working with Duke Health to implement a comprehensive cardiovascular information system (CVIS) for Duke’s non-...

NASH Race Heats up as Viking Therapeutics Announces Stellar Phase II Data http://dlvr.it/QkbTsZ pic.twitter.com/qOvFosyEmr

NASH Race Heats up as Viking Therapeutics Announces Stellar Phase II Data http://dlvr.it/QkbTsZ  pic.twitter.com/qOvFosyEmr

Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe

Hemispherx Biopharma (NYSE:HEB) announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen (rintatolimod), which is slated for multiple uses including product launch in Argentina, where Ampligen is approved for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), ME/CFS expanded access program (EAP) in t...

Offer histopathology trainees “golden hellos” to bolster numbers, says college

Just 3% of NHS histopathology departments have enough staff to meet clinical demand, a workforce census by the Royal College of Pathologists has found.1In a report on the census findings, the college...

JEFF $VKTX key Takeaway NASH competitor VKTX reported stat sig "positive" Phase II data that looks promising which adds to the growing list of "positive" NASH drugs.

JEFF $VKTX key Takeaway NASH competitor VKTX reported stat sig "positive" Phase II data that looks promising which adds to the growing list of "positive" NASH drugs.

Biocom Applauds Introduction of Rare Disease Fund Act

Biocom, the association representing the life science industry of California, today applauded the introduction of H.R. 6801, the Rare Disease (RaD) Fund Act by U.S. Representatives Juan Vargas (D-CA), Scott Peters (D-CA) and Tom Rooney (R-FL). Click here to view the legislation. The statement can be attributed to Joe Panetta, Biocom’s president and CEO: ...

Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

Medtronic Receives FDA Approval for Revised TAVR Labeling and Begins Investigational Study of Low Risk Patients with Bicuspid Valves DUBLIN - September 18, 2018 - Medtronic plc (NYSE:MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a single-arm study to evaluate the CoreValve Evolut(TM)TAVR syst...

Promising Gene Therapy for Visually Impaired Sheep Now Safe for Human Trials

NewsBased on promising findings, the FDA has approved clinical trials for human patients and several U.S. medical centers have already begun using this therapy to treat patients with achromatopsia.

The U.S. government has approved the importation of marijuana extracts from Canada for a clinical trial. https://buff.ly/2D87MVs 

The U.S. government has approved the importation of marijuana extracts from Canada for a clinical trial. https://buff.ly/2D87MVs 

Arix Biosciences’ investee company Iterum kicks off phase III trials of next-generation antibiotic

Unlike most penem drugs, Iterum’s sulopenem can be taken orally, which is why analysts think it has the potential to become a blockbuster antibiotic drug

In a rare move, the U.S. government has approved the importation of marijuana extracts from Canada for a clinical trial. https://buff.ly/2phmxeJ 

In a rare move, the U.S. government has approved the importation of marijuana extracts from Canada for a clinical trial. https://buff.ly/2phmxeJ 

Science has helped advance our understanding of #severeasthma, but it may remain uncontrolled. We're committed to redefining how severe #asthma is managed. To achieve this, we've embarked on a program called PRECISION. Dr. Lykke shares more: http://bit.l

Science has helped advance our understanding of #severeasthma, but it may remain uncontrolled. We're committed to redefining how severe #asthma is managed. To achieve this, we've embarked on a program called PRECISION. Dr. Lykke shares more: http://bit.ly/2NHByo0 . #ERSCongress pic.twitter.com/OPIbyZRGFl


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks